Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Thermo Fisher Scientific enters its October 21 earnings release with the Street turning more explicitly bullish, two bellwether upgrades landing on the same morning and the stock within striking distance of consensus targets that have moved sharply higher in the past week.
The standout development is the analyst activity from Tuesday. Morgan Stanley raised its target on TMO from $650 to $730, keeping an Overweight rating, while TD Cowen lifted from $675 to $760, also maintaining Buy. Both actions landed on October 13, the same day. That follows Barclays moving its target from $650 to $750 last week. Three target raises in eight days, all from firms carrying positive ratings, has pulled the mean Street target to $683.84 against a current price of $663.04. That implies modest upside on consensus math alone, but the direction of travel matters more: as recently as late July, the Morgan Stanley target was $650 and Barclays was at $625. The Street has repriced sharply ahead of the print. Not everyone is aligned, Piper Sandler holds a Neutral at $600 and RBC sits at Sector Perform with a $580 target, both from late July, but the balance of recent activity is one-directional.
The bull case centres on life science solutions revenue growing at roughly 5.4% compounding over the next three years, an EPS growth rate projected at 8.5% annually over four years, and Thermo Fisher's positioning in biopharma clinical trial outsourcing through its Clario acquisition. Bears point to margin erosion: adjusted EBIT margin has fallen around 830 basis points from 2021 to 2024, and the adjusted gross margin is well below its 2019 peak. Biotech funding headwinds have also been real, with capital raised by early-stage companies declining sharply in 2025. Valuation reflects the recovery trade: the PE multiple has expanded about 1.6 points over the past 30 days to 24.5x, and price-to-book has moved from roughly 3.76 to 4.05 over the same stretch. The EV/EBITDA multiple at 20.8x has drifted slightly lower over the month, a small offset.
Short positioning is not a story here. Short interest is just 1.4% of the free float, about 5.25 million shares. That figure has risen roughly 7% over the past week, and is up 13% over the past month, but from such a low base the absolute level is trivial. Borrow availability is as loose as it gets, shares to lend vastly outnumber shares borrowed. Cost to borrow has crept up 19% over the week to 0.48%, its highest point in a month, but at sub-half-a-percent it signals nothing. Options positioning is equally calm. The put/call ratio is 0.84, almost exactly in line with its 20-day average of 0.84, and the z-score of 0.03 is statistically flat. There is no hedging build, no short squeeze dynamic, no borrow squeeze. The lending market is inert.
The earnings history adds useful texture without making a directional argument. The last print, on July 23, produced a one-day gain of 7.9% and a five-day gain of 9.6%. The print before that showed a one-day move of 9.3% and a five-day move of 10.1%. Both episodes produced positive reactions of a similar order of magnitude. The stock is up nearly 9% over the past month heading into October 21, so some of that optimism is already in the price.
Peer moves this week were broadly positive. DHR gained 3.4% on the week and MEDP added 1.2%, while CRL fell 1.9% and WAT lost 1.7%. TMO's 1% weekly gain sits in the middle of that range, neither leading nor lagging the group meaningfully.
What to watch next is whether the October 21 print confirms the margin trajectory that analysts have started pricing back in, or whether the EBIT pressure the bear case describes shows up again in the numbers.
See the live data behind this article on ORTEX.
Open TMO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
